Welcome to our dedicated page for Alector SEC filings (Ticker: ALEC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alector, Inc. filings document a Nasdaq-listed biotechnology issuer developing therapies for neurodegenerative diseases and reporting progress across the Alector Brain Carrier (ABC) platform. Its 8-K reports include operating and financial results, clinical and portfolio updates, material agreements, and officer appointments.
Regulatory documents also cover the company’s common stock, shelf registration statement and at-the-market equity sales agreement, along with governance matters in proxy materials such as board elections, executive compensation and shareholder voting items. Clinical disclosures address programs in Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia and related neurological disorders, while event filings frame capital resources, platform development, trial outcomes and pipeline changes.
SCHELLER RICHARD H reported acquisition or exercise transactions in this Form 4 filing.
Alector director Richard H. Scheller received an equity grant of 10,833 shares of Common Stock in the form of restricted stock units. These RSUs vest in four equal quarterly installments beginning on June 1, 2026. After this award, he holds 106,199 shares directly.
Alector, Inc. Chief Executive Officer Arnon Rosenthal reported a disposition of 87,216 shares of common stock on June 2, 2026 at a weighted average price of $1.9743 per share. The shares were sold to satisfy tax obligations from vesting restricted stock units, leaving him with 2,367,206 shares held directly, plus additional indirect holdings through family trusts.
Alector, Inc. principal accounting officer Grace Wong-Sarad reported open-market sales of company common stock that were made to satisfy tax obligations from vesting restricted stock units. She sold a total of 9,184 shares over two days under a pre-arranged Rule 10b5-1 trading plan and continues to hold 95,461 shares.
Alector, Inc. executive Neil Lindsay Berkley, the CFO & Chief Business Officer, reported an open-market sale of 19,360 shares of common stock on June 2, 2026 at a weighted average price of $1.9742 per share. According to the disclosure, these shares were sold to satisfy his tax obligations arising from the vesting of restricted stock units. After this tax-related sale, Berkley directly holds 379,900 shares of Alector common stock.
Alec Rarely, Inc. (ALEC) submitted a Form 144 notice reporting an intended sale of 3,475 shares of Common stock described as Restricted Stock with an issuance/offer date of 06/01/2026. The filing also lists three prior sales by Grace Wong-Sarad of 5,709, 1,820, and 1,000 common shares on 06/02/2026, 04/16/2026, and 03/10/2026, respectively.
Alector, Inc. submits a Rule 144 notice regarding recent common stock activity. The filing records the vesting of 10,295 Restricted Stock Units on 06/01/2026 and lists multiple prior open-market dispositions by Grace Wong-Sarad in Feb–Apr 2026. The securities are Common Stock listed on Nasdaq.
Alector, Inc. filed a Form 144 notice reporting proposed sales tied to the vesting of Restricted Stock Units. The filing lists 35,795 shares related to RSU vesting on 06/01/2026.
The excerpt also shows 29,649 shares reported as sold on 03/02/2026 in the prior three months. The filing is a routine sale notice under the securities resale rules.
Alector, Inc. filed a Form 144 notifying the proposed sale of 132,805 shares of Common Stock tied to the vesting of restricted stock units on 06/01/2026. The notice also records prior dispositions of 81,864 shares on 03/02/2026 producing $173,825.38 in proceeds. The transactions are reported in connection with brokerage arrangements through Morgan Stanley Smith Barney and list Nasdaq as the market.
Alector, Inc. amendment to a previously filed Schedule 13G/A updates beneficial ownership information for Polaris-related entities and specified individuals as of April 30, 2026.
The filing lists holdings across Polaris funds: Polaris Venture Partners VI (498,468 shares, 0.5%), Polaris Venture Partners Founders' Fund VI (267,979 shares, 0.2%), PVP VI (AIV) (3,280,842 shares, 3.0%), and PVP VI (AIV-B) (806,528 shares, 0.7%). Polaris Venture Management Co. VI, L.L.C. reports shared voting/dispositive power over 4,853,817 shares (4.4%), based on 110,362,581 shares outstanding as of February 20, 2026 per the annual report cited.
Named individuals—David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, Amir Nashat, and Bryce Youngren—are reported with shared voting and dispositive power attributable to their roles at Polaris. Mr. McGuire's total includes 26,250 restricted stock units, producing a combined figure that the amendment cites as 110,388,831 when calculating his percent figure.
Alector, Inc. entered into a new Sales Agreement with TD Securities (USA) LLC that allows it to offer and sell up to $125,000,000 of common stock through an at-the-market program under its effective shelf registration.
Shares may be sold from time to time on The Nasdaq Global Select Market or through other permitted methods, with Alector setting parameters such as timing, share amounts, daily limits, and minimum prices. TD Cowen may receive up to 3.0% of the gross sales price as compensation. Alector plans to use any net proceeds for general corporate purposes, including research, development and manufacturing of product candidates, working capital, capital expenditures, other corporate expenses, and potential acquisitions or strategic transactions.